Abstract
Background
There is increasing concern that the use of second-generation antipsychotic medications in schizophrenia is associated with the development of metabolic syndrome.
Aims
This study assessed the prevalence and clinical associations of metabolic syndrome among patients receiving clozapine within the catchment area of a mental health service in the west of Ireland.
Method
A total of 84 patients (96% response rate) taking clozapine were interviewed and thoroughly investigated using physical assessments, comprehensive laboratory testing and review of medical records.
Results
Of the patients, 46.4% taking clozapine fulfilled the criteria for metabolic syndrome. Male gender, high body mass index, high insulin level and receiving a concomitant antipsychotic medication were significantly associated with the presence of metabolic syndrome.
Conclusion
Almost half of the patients receiving clozapine have metabolic syndrome and are consequently at risk of cardiovascular morbidity and mortality. Such patients should be closely monitored in order to facilitate interventions, which could alleviate the adverse health consequences of this syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716
Curkendall SM, Jingping M, Glasser DB et al (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Br J Psychiatry 65:715–720
Ryan MC, Thakore JH (2002) Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239–257
Brown S (1997) Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 171:502–508
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289
Dixon L, Weiden P, Delahanty J et al (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903–912
Holmberg SK, Kane C (1999) Health and self-care practices of persons with schizophrenia. Psychiatr Serv 50:827–829
De Hert M, Van Eyeck D, De Nayer A (2006) Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21:1–5
Chakos M, Lieberman J, Hoffman E et al (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and metaanalysis of randomized trials. Am J Psychiatry 158:518–526
Allison DB, Mentore JM, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696
Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17
Casey DE (2004) Dyslipidemia and atypical antipsychoic drugs. J Clin Psychiatry 65:27–35
Henderson DC, Daley TB, Kunkel L et al (2004) Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65:686–689
Annual Report (2006); Mental Health Commission, Ireland
Kottke BA, Zinsmeister AR, Holmes DR et al (1986) Apolipoproteins and coronary artery disease. Mayo Clin Proc 61:313–320
Ridker PM, Buring JE, Cook NR et al (2003) C-reactive protein, the metabolic syndrome, and the risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397
International Diabetes Federation (2005) The IDF consensus worldwide definition of the metabolic syndrome; Brussels, International Diabetes Federation (online). http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf
Barter PJ, Connor WE (1975) The transport of triglycerides in the high-density lipoproteins of human plasma. J Lab Clin Med 85:261–272
Lagrost L, Gambert P, Meunier S et al (1989) Correlation between apolipoprotein A-IV and triglyceride concentrations in human sera. J Lipid Res 30(5):701–710
Kane JP (1983) Apolipoprotein B: structural and metabolic heterogeneity. Ann Rev Physiol 45:637–650
Friedewald WT, Levy RI, Fredickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem 18(6):499–502
SPSS (Statistical Package for the Social Sciences) (2005) SPSS for Windows version 14, release 14.0.1,Chicago, SPSS Inc
Villegas R, Perry IJ, Creagh D et al (2003) The prevalence of the metabolic syndrome in middle-age men and women. Diabetes Care 11:3198–3199
De Nayer A, De Hert M, Scheen A et al (2005) Belgian consensus on metabolic problems associated with second-generation antipsychotics: conference report. Int J Psychiatr Clin Pract 9:130–137
Marder SR, Essock SM, Miller AL et al (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349
The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines (1992) World Health Organization
National Institute for Health and Clinical Excellence (2002) Schizophrenia clinical guidelines
Acknowledgments
Special thanks are due to Esther Courtney, Peggy Gilligan, Jacqueline O’Loughlen and Joe Tanian for their assistance in data collection.
Declaration of interest:
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahmed, M., Hussain, I., O’Brien, S.M. et al. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci 177, 205–210 (2008). https://doi.org/10.1007/s11845-008-0156-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0156-9